Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) Director Laura Brege sold 14,167 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This represents a 47.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Mirum Pharmaceuticals Stock Performance
Mirum Pharmaceuticals stock opened at $93.99 on Monday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.07 and a quick ratio of 1.98. Mirum Pharmaceuticals, Inc. has a one year low of $63.23 and a one year high of $130.00. The stock has a market capitalization of $6.14 billion, a PE ratio of -6.08 and a beta of 0.75. The business’s fifty day moving average is $88.79 and its 200 day moving average is $98.41.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The business had revenue of $185.72 million during the quarter, compared to the consensus estimate of $178.07 million. During the same quarter in the previous year, the business posted $0.05 earnings per share. Mirum Pharmaceuticals’s quarterly revenue was up 39.6% compared to the same quarter last year. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.
Institutional Trading of Mirum Pharmaceuticals
A number of hedge funds have recently bought and sold shares of MIRM. Janus Henderson Group PLC grew its position in shares of Mirum Pharmaceuticals by 14.5% during the 1st quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth $691,672,000. BlackRock Inc. purchased a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth $513,945,000. William Blair Investment Management LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter worth $164,453,000. Finally, Rock Springs Capital Management LP raised its holdings in Mirum Pharmaceuticals by 6.4% in the 1st quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock worth $74,947,000 after purchasing an additional 49,000 shares during the period.
Analyst Ratings Changes
MIRM has been the topic of a number of recent analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $155.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. Stifel Nicolaus boosted their price objective on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Leerink Partners lowered their price objective on shares of Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. UBS Group set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Finally, Cantor Fitzgerald raised their target price on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.56.
Read Our Latest Stock Analysis on Mirum Pharmaceuticals
Mirum Pharmaceuticals Company Profile
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Recommended Stories
- Five stocks we like better than Mirum Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
